Sign in

CIK 0001157601 · Large accelerated filer

MADRIGAL PHARMACEUTICALS, INC.

Sign in to watch
Ticker
MDGL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
(267) 824-2827
Business address
1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
Former names
MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
Open-market buys, last 90 days
$35,023,032
in 1 filing
Open-market sales, last 90 days
$7,011,938
in 3 filings, $6.7M under 10b5-1 plans

Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. BAKER BROS. ADVISORS LP +$35.0M Director 1 filing
  2. Sibold William John −$6.2M President and CEO sold 6% of stake
  3. Kelley Shannon T −$773K General Counsel sold 14% of stake
Date Insider Transaction Shares Price Value Owned after
2023-01-17 Levy Richard S Director Sale −100 $285.28 $29K 31,489
2023-01-17 Levy Richard S Director Sale −400 $287.08 $115K 31,089
2023-01-17 Levy Richard S Director Sale −300 $288.91 $87K 30,789
2023-01-17 Levy Richard S Director Sale −1,600 $290.36 $465K 29,189
2023-01-17 Levy Richard S Director Sale −3,325 $291.66 $970K 25,864
2023-01-17 Levy Richard S Director Sale −5,227 $292.68 $1.5M 20,637
2023-01-17 Levy Richard S Director Sale −3,548 $293.54 $1.0M 17,089
2023-01-17 Levy Richard S Director Sale −5,164 $294.68 $1.5M 11,925
2023-01-17 Levy Richard S Director Sale −2,325 $295.45 $687K 9,600
2023-01-17 Levy Richard S Director Sale −500 $296.68 $148K 9,100
2023-01-17 Levy Richard S Director Option exercise · Stock Option (Right to buy) −12,489 0
2023-01-17 Levy Richard S Director Option exercise · Stock Option (Right to Buy) −10,000 0
2023-01-16 FRIEDMAN PAUL A Director Shares withheld for taxes −2,254 $243.92 $550K 20,001
2023-01-16 Sukhija Remy Chief Commercial Officer Grant or award +15,001 15,001
2023-01-16 Waltermire Robert E. Senior VP, Chief Pharma Dev. Grant or award +5,667 5,667
2023-01-16 Lynch Brian Joseph SVP and General Counsel Grant or award +15,001 15,001
2023-01-16 Howarth Alex G. Chief Financial Officer Grant or award +15,001 15,001
2023-01-16 FRIEDMAN PAUL A Chief Executive Officer Grant or award +26,668 26,668
2023-01-16 Taub Rebecca Pres., R&D, and CMO Grant or award +20,001 20,001
2023-01-03 Lynch Brian Joseph SVP and General Counsel Option exercise +13,000 $91.79 $1.2M 13,000

Page 48 of 82 · 1,629 trades